GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Capex-to-Operating-Income

IRLAB Therapeutics AB (OSTO:IRLAB A) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

IRLAB Therapeutics AB's Capital Expenditure for the three months ended in Mar. 2024 was kr0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was kr-37.64 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


IRLAB Therapeutics AB Capex-to-Operating-Income Historical Data

The historical data trend for IRLAB Therapeutics AB's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Capex-to-Operating-Income Chart

IRLAB Therapeutics AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.01 - -

IRLAB Therapeutics AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of IRLAB Therapeutics AB's Capex-to-Operating-Income

For the Biotechnology subindustry, IRLAB Therapeutics AB's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRLAB Therapeutics AB's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Capex-to-Operating-Income falls into.



IRLAB Therapeutics AB Capex-to-Operating-Income Calculation

IRLAB Therapeutics AB's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.293) / -180.766
=N/A

IRLAB Therapeutics AB's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -37.636
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IRLAB Therapeutics AB  (OSTO:IRLAB A) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


IRLAB Therapeutics AB Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


IRLAB Therapeutics AB (OSTO:IRLAB A) Business Description

Traded in Other Exchanges
Address
Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB (OSTO:IRLAB A) Headlines

No Headlines